Cargando…

A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions

In order to understand the link between substantia nigra pars compacta (SNc) cell loss and Parkinson's disease (PD) symptoms, we developed a multiscale computational model that can replicate the symptoms at the behavioural level by incorporating the key cellular and molecular mechanisms underly...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Sandeep Sathyanandan, Muddapu, Vignayanandam Ravindernath, Chakravarthy, V. Srinivasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762321/
https://www.ncbi.nlm.nih.gov/pubmed/35046787
http://dx.doi.org/10.3389/fncom.2021.756881
_version_ 1784633737182445568
author Nair, Sandeep Sathyanandan
Muddapu, Vignayanandam Ravindernath
Chakravarthy, V. Srinivasa
author_facet Nair, Sandeep Sathyanandan
Muddapu, Vignayanandam Ravindernath
Chakravarthy, V. Srinivasa
author_sort Nair, Sandeep Sathyanandan
collection PubMed
description In order to understand the link between substantia nigra pars compacta (SNc) cell loss and Parkinson's disease (PD) symptoms, we developed a multiscale computational model that can replicate the symptoms at the behavioural level by incorporating the key cellular and molecular mechanisms underlying PD pathology. There is a modelling tradition that links dopamine to reward and uses reinforcement learning (RL) concepts to model the basal ganglia. In our model, we replace the abstract representations of reward with the realistic variable of extracellular DA released by a network of SNc cells and incorporate it in the RL-based behavioural model, which simulates the arm reaching task. Our results successfully replicated the impact of SNc cell loss and levodopa (L-DOPA) medication on reaching performance. It also shows the side effects of medication, such as wearing off and peak dosage dyskinesias. The model demonstrates how differential dopaminergic axonal degeneration in basal ganglia results in various cardinal symptoms of PD. It was able to predict the optimum L-DOPA medication dosage for varying degrees of cell loss. The proposed model has a potential clinical application where drug dosage can be optimised as per patient characteristics.
format Online
Article
Text
id pubmed-8762321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87623212022-01-18 A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions Nair, Sandeep Sathyanandan Muddapu, Vignayanandam Ravindernath Chakravarthy, V. Srinivasa Front Comput Neurosci Neuroscience In order to understand the link between substantia nigra pars compacta (SNc) cell loss and Parkinson's disease (PD) symptoms, we developed a multiscale computational model that can replicate the symptoms at the behavioural level by incorporating the key cellular and molecular mechanisms underlying PD pathology. There is a modelling tradition that links dopamine to reward and uses reinforcement learning (RL) concepts to model the basal ganglia. In our model, we replace the abstract representations of reward with the realistic variable of extracellular DA released by a network of SNc cells and incorporate it in the RL-based behavioural model, which simulates the arm reaching task. Our results successfully replicated the impact of SNc cell loss and levodopa (L-DOPA) medication on reaching performance. It also shows the side effects of medication, such as wearing off and peak dosage dyskinesias. The model demonstrates how differential dopaminergic axonal degeneration in basal ganglia results in various cardinal symptoms of PD. It was able to predict the optimum L-DOPA medication dosage for varying degrees of cell loss. The proposed model has a potential clinical application where drug dosage can be optimised as per patient characteristics. Frontiers Media S.A. 2022-01-03 /pmc/articles/PMC8762321/ /pubmed/35046787 http://dx.doi.org/10.3389/fncom.2021.756881 Text en Copyright © 2022 Nair, Muddapu and Chakravarthy. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Nair, Sandeep Sathyanandan
Muddapu, Vignayanandam Ravindernath
Chakravarthy, V. Srinivasa
A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions
title A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions
title_full A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions
title_fullStr A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions
title_full_unstemmed A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions
title_short A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions
title_sort multiscale, systems-level, neuropharmacological model of cortico-basal ganglia system for arm reaching under normal, parkinsonian, and levodopa medication conditions
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762321/
https://www.ncbi.nlm.nih.gov/pubmed/35046787
http://dx.doi.org/10.3389/fncom.2021.756881
work_keys_str_mv AT nairsandeepsathyanandan amultiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions
AT muddapuvignayanandamravindernath amultiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions
AT chakravarthyvsrinivasa amultiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions
AT nairsandeepsathyanandan multiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions
AT muddapuvignayanandamravindernath multiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions
AT chakravarthyvsrinivasa multiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions